Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
Best Penny Stocks To Buy Now? 7 Insider Picks In November
Penny Stocks To Buy: 7 Insider Picks For November 2022
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Satsuma Pharmaceuticals to Present at SVB Leerink's CNS Forum
STSA Stock Price Increases Over 15% Pre-Market: Why It Happened
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights
Why Earnings Season Could Be Great for Satsuma Pharmaceuticals (STSA)
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Satsuma: Launch Of 2nd Pivotal Trial For Migraine Med Ought To Cheer Share Price
Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences
Thomas P. O’neil Sells 2,115 Shares of Satsuma Pharmaceuticals (NASDAQ:STSA) Stock
Sterling Financial Corporation of Spokane, Wash., Announces Date for 2013 Fourth-Quarter and Year-End Earnings Release and Conference Call